'Vyloy,' a targeted therapy for gastric cancer with a novel mechanism of action, is expected to be launched in South Korea.

According to industry sources, Astellas Korea has submitted an application for approval of Vyloy (zolbetuximab), a treatment for claudin 18.2 (CLDN18.2) positive, HER2-negative, unresectable, advanced, or recurrent gastric cancer.

In March, it acquired the final approval in Japan.

Vyloy is a monoclonal antibody targeting CLDN18.2, which is expressed in the stomach. Its mechanism of action involves binding to CLDN18.2, a protein expressed on the cancer cell membrane of gastric epithelial cells.

The efficacy of Vyloy was proven throug